Summary
Edwards Lifesciences Corporation reported solid performance for the fiscal year ended December 31, 2018, with total net sales increasing by 8.4% to $3.72 billion. The company's Transcatheter Heart Valve Therapy (THVT) segment was the primary growth driver, with sales up 12.8%, largely attributable to the strong adoption of the Edwards SAPIEN 3 valve. Surgical Heart Valve Therapy (SHVT) experienced a slight decline in sales, primarily due to a sales return reserve related to a change in inventory models, though underlying demand for surgical aortic tissue valves remained positive. Operational efficiency was also a focus, with gross profit margin improving due to a favorable product mix. The company continued to invest heavily in research and development, with 16.7% of net sales dedicated to innovation, including advancements in transcatheter mitral and tricuspid therapies. Significant events during the year included regulatory approvals for the SAPIEN 3 Ultra system and the Acumen Hypotension Prediction Index, and a settlement agreement for patent disputes with Boston Scientific in early 2019. The company also managed its capital structure effectively, repurchasing shares and maintaining a strong liquidity position.
Financial Highlights
56 data points| Revenue | $3.72B |
| Cost of Revenue | $939.40M |
| Gross Profit | $2.78B |
| R&D Expenses | $622.20M |
| SG&A Expenses | $1.09B |
| Operating Income | $748.20M |
| Interest Expense | $29.90M |
| Net Income | $722.20M |
| EPS (Basic) | $1.15 |
| EPS (Diluted) | $1.13 |
| Shares Outstanding (Basic) | 627.60M |
| Shares Outstanding (Diluted) | 640.90M |
Key Highlights
- 1Net sales grew 8.4% to $3.72 billion, driven by strong performance in Transcatheter Heart Valve Therapy (THVT).
- 2THVT sales increased 12.8%, primarily due to the widespread adoption of the Edwards SAPIEN 3 valve.
- 3Surgical Heart Valve Therapy (SHVT) sales decreased 5.6%, mainly due to a sales return reserve related to a consignment inventory model conversion.
- 4Gross profit margin improved due to a more favorable product mix, with THVT products leading the way.
- 5Research and Development (R&D) spending represented 16.7% of net sales, underscoring the company's commitment to innovation.
- 6The company settled patent disputes with Boston Scientific for $180 million in early 2019, a charge recorded in 2018.
- 7Edwards Lifesciences maintained a solid financial position with $714.1 million in cash and cash equivalents and no outstanding borrowings on its credit facility at year-end.